Skip to content
Peptidepedia

Thymosin Alpha 1 Dosage Guide: Protocols, Timing & How Much to Take (2026)

From Peptidepedia, the trusted peptide wiki.

Dosage Protocols

Immune Enhancement/Maintenance: 1.6 mg subcutaneously twice weekly. This is the most common starting dose for general immune support and has demonstrated efficacy in clinical settings with minimal adverse effects.

Acute Viral Infections/Cancer Adjunct Therapy: 1.6 mg daily or 3.2 mg twice weekly for initial treatment phases, potentially extending to 6.4 mg twice weekly in severe cases under medical supervision. Clinical trials in hepatitis B employed 1.6 mg twice weekly for 6-12 months.

Cycling Considerations: Unlike anabolic compounds, Thymosin Alpha 1 does not appear to induce receptor downregulation or tachyphylaxis with extended use. Many practitioners employ continuous protocols for chronic conditions, though some prefer 8-12 week cycles followed by 4-week breaks for prophylactic use.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Goldstein AL, et al. Thymosin alpha 1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci USA. 1977.
  2. Romani L, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through Toll-like receptor signaling. Blood. 2004.
  3. Garaci E, et al. Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application. Int J Immunopharmacol. 2000.
  4. Wu J, et al. Thymosin alpha 1 treatment reduces mortality in severe sepsis patients. Crit Care. 2013.
  5. Chien RN, et al. Thymosin alpha 1 in the treatment of chronic hepatitis B: a randomized controlled trial. Hepatology. 1998.
  6. You J, et al. Meta-analysis: thymalfasin for chronic hepatitis B. Aliment Pharmacol Ther. 2009.
  7. Andreone P, et al. Thymosin alpha 1 plus interferon alpha for hepatitis C. J Viral Hepat. 2006.
  8. Garaci E, et al. Thymosin alpha 1 in cancer treatment. Ann N Y Acad Sci. 2010.
  9. Gravenstein S, et al. Augmentation of influenza antibody response in elderly men by thymosin alpha 1. J Am Geriatr Soc. 1989.
  10. Tuthill C, et al. Thymalfasin: biological properties and clinical applications. Int Immunopharmacol. 2010.
←Read the full Thymosin Alpha 1 guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”